# Comparison of Daily Single Dose Triple and Conventional Triple Therapies for Helicobacter Pylori Infection

> **NCT02711176** · PHASE4 · COMPLETED · sponsor: **Zahra Vahdat Shariatpanahi** · enrollment: 212 (actual)

## Conditions studied

- Helicobacter Infection

## Interventions

- **DRUG:** Nexium
- **DRUG:** Tinafas
- **DRUG:** Tavanex
- **DRUG:** Lanzol
- **DRUG:** Klacid
- **DRUG:** Iramox

## Key facts

- **NCT ID:** NCT02711176
- **Lead sponsor:** Zahra Vahdat Shariatpanahi
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09
- **Primary completion:** 2017-03-27
- **Final completion:** 2017-03-27
- **Target enrollment:** 212 (ACTUAL)
- **Last updated:** 2017-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02711176

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02711176, "Comparison of Daily Single Dose Triple and Conventional Triple Therapies for Helicobacter Pylori Infection". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02711176. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*